Please assess the completion status of the following clinical trial:

Trial Title: Bromocriptine and Pentoxifylline in Ophthalmopathy Autoimmune Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Women or men~* Between 18 and 45 years~* Autoimmune hyperthyroidism with one year or less of evolution~* No previous treatment~* Mild to moderate ophthalmopathy~Exclusion Criteria:~* Smoking~* Severe ophthalmopathy~* Steroid treatment~* Asthma~* Diabetes or other significant disease~* Creatine \>1.5 mg/dl~* Women with child bearing potential not using a birth control method~* Opthalmologic diseases~* Uncontrolled hypertension~* History of ischemic cardiopathy~* History of stroke~* History of gastrointestinal bleeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- methimazole (Type: ACTIVE_COMPARATOR): methimazole 30 mg daily during one year
- methimazole, bromocriptine (Type: ACTIVE_COMPARATOR): methimazole 30 mg daily during one year, bromocriptine 5 mg twice a day during one year
- pentoxifylline (Type: ACTIVE_COMPARATOR): methimazol 30 mg daily and pentoxifylline 400 mg twice a day during one year

Based on this trial design, predict the completion outcome and termination type (if applicable).